The 2015 World Health Organization (WHO) classification of lung tumors results from an integrated multi-disciplinary approach involving radiology, molecular biology, and medical oncology (Travis et al., 2015). We analyzed the RNA-seq data of ZDHHC5 in LUAD pathological types (Figure 2E). Immunohistochemical (IHC) results of LUAD and normal lung tissue from the Human Protein Atlas (HPA) database (Uhlén et al., 2015) were obtained to be determined (Figure 2F). Basic annotation parameters were scored for the HPA samples by pathologists. ZDHHC5 was stained in over 75% of tumor cells, including medium and low expression LUADs. In lung normal tissues, ZDHHC5 was highly stained in macrophages, with a high fraction (>75%) of stained cells. However, ZDHHC5 showed medium-staining intensity in only 25–75% alveolar cells, which was lower than in the LUAD. Different pathological types represent different prognoses: lepidic represent good, acinar, and papillary standing for intermediate, and micropapillary and solid representing worse prognosis. The clinicopathological diagnosis of LUAD reports the percentage of all types in increments of 5%. Thus, we evaluated the histological subtype of the IHC results and reported the percentage of
